Treatment Patterns in Family Medicine: The Role of the Primary Care Clinician in Patient-Centered Management of IBD: Module 1: Diagnosis and Initial Treatment Options
Released: September 16, 2016
Expires: October 14, 2017
• CE for this activity will not be available after this date.
• A participation code will be provided at the end of the CE activity. See below for details.
IBD can be challenging to diagnose because of its heterogeneous and somewhat ambiguous clinical presentation. Despite the challenges, primary care clinicians are on the front line for assessment and initial diagnosis of these patients. Once diagnosed, even if placed under the care of a gastroenterologist, these patients will require life-long care. This activity, the first in a 3-part series, addresses diagnosis and initial treatment options for IBD, as well as collaboration between primary care clinicians and specialists.
After completion of this activity participants will be better able to:
• Discuss the signs and symptoms of IBD.
• Outline the differential diagnosis for ulcerative colitis and Crohn’s disease.
• Review currently available first-line treatment options and their associated benefits and risks.
Bret A. Lashner, MD
Elliot B. Davidson, MD, FAAFP
This activity was planned in accordance with AANP Accreditation Standards and Policies. Developed by the New Jersey Academy of Family Physicians (NJAFP), the American Association of Nurse Practitioners (AANP), and the American Academy of PAs (AAPA) in cooperation with MCM Education, this CE activity is supported by educational grants from Shire; AbbVie, Inc.; and Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America, LLC. .
Bret A. Lashner, MD, has no conflicts of interest to disclose.
Elliot B. Davidson, MD, FAAFP, has no conflicts of interest to disclose.
Lauren Carruth, MD, has no conflicts of interest to disclose.
Alana R. Wichmann, APN, has disclosed the following: Speaker’s Bureau with AbbVie, Inc
Eric Peterson, EdM, FACEHP, CHCP, has no conflicts of interest to disclose.
To complete the CE for this activity, review all the content, successfully complete on the online post-test and submit the online program evaluation. At the end of the program, you will receive the participation code to complete the posttest/evaluation for the activity and claim credit. In the AANP CE Center for this program, click Get Certificate and choose Participation Codes. Enter the code provided and the posttest/evaluation will be available to you.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Post Impact Survey:
Between 30 to 90 days after this activity is completed, AANP will send out an invitation to participate in a Post Impact Outcomes Survey (PI Survey) . Participation in the survey is optional and does not affect the credit earned. The PI surveys help measure the overall impact of the education content, see how the material impacts practice behaviors and what changes are being made. This anonymous information is crucial in helping the Education department improve current activities as well as guiding AANP in planning future CE activities.
For questions or more information concerning the AANP CE Center, or this online CE opportunity, please contact the AANP CE Center Manager at CECenter@aanp.org.